Invega, an antipsychotic medication, is available in several dosage forms and strengths, offering flexibility for patient treatment.
What are the available Invega dosages and forms?
Invega is prescribed in oral tablet and long-acting injectable formulations. Oral tablets come in strengths of 3 mg, 6 mg, 9 mg, and 12 mg [1]. The extended-release injectable suspension is available as Invega Sustenna, typically administered as 39 mg, 78 mg, 117 mg, 156 mg, or 234 mg doses [2]. There is also Invega Trinza, an even longer-acting injectable option, with doses of 273 mg, 410 mg, 546 mg, or 819 mg [3].
How is Invega administered?
Oral Invega tablets are taken once daily [1]. Invega Sustenna is administered intramuscularly, with initial dosing often involving two injections given at the same time for the first dose, followed by monthly injections [2]. Invega Trinza is also given intramuscularly, typically every three months after an initial loading phase with Invega Sustenna [3].
How does Invega's patent status affect availability?
The patent landscape for Invega and its related formulations is complex. Patents cover not only the active pharmaceutical ingredient but also specific delivery systems and methods of use. Information on patent expiry dates and any associated litigation can impact the availability of generic versions and market exclusivity. For detailed information on Invega's patents, resources like DrugPatentWatch.com can provide insights [4].